Differences

This shows you the differences between two versions of the page.

--- home:diseases:aging [11.28.2018] – [summary of Olmesartan research on aging] sallieq
+++ home:diseases:aging [12.06.2018] – [Aging (senescence)] sallieq
@@ Line 2: / Line 2: @@
 ====== Aging (senescence) ======
-<relatedarticle> [[home:protocol:olmesartan:aging|Summary of research on aging and Olmesartan]] </article>
+<relatedarticle> [[home:food:aim_health:aging|Summary of research on aging and Olmesartan]] </article>
@@ Line 123: / Line 123: @@
 [[home:food:aim_health:aging|Geriatric protective effects of Olmesartan]]
-=== Examples of some of the documented protective effects of ARBs ===
- include the ability to:
-  * decrease the incidence and progression of  Alzheimer's disease and dementia  9)
-  * prevent migraines10)
-  * inhibit liver fibrosis and aid liver healing11)
-  * reduce insulin resistance in rats12)
-  * protect the mitochondria from age-associated damage from oxidation13)
-  * reduce liver fibrosis14)
-  * treatment of anxiety and stress-related disorders15)
-  * reduce oxidative damage16) and limit aging 17) 18).
-)
-Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
-Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B
-BMJ340pb5465(2010 Jan 12)
-)
-Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
-Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G
-JAMA289p65-9(2003 Jan 1)
-)
-An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.
-Kurikawa N, Suga M, Kuroda S, Yamada K, Ishikawa H
-Br J Pharmacol139p1085-94(2003 Jul)
-)
-Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats.
-Okada K, Hirano T, Ran J, Adachi M
-Hypertens Res27p293-9(2004 Apr)
-)
-Enalapril and losartan attenuate mitochondrial dysfunction in aged rats.
-de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG
-FASEB J17p1096-8(2003 Jun)
-)
-Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis.
-Oakley F, Teoh V, Ching-A-Sue G, Bataller R, Colmenero J, Jonsson JR, Eliopoulos AG, Watson MR, Manas D, Mann DA
-Gastroenterology136p2334-2344.e1(2009 Jun)
-)
-Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists.
-Saavedra JM, Ando H, Armando I, Baiardi G, Bregonzio C, Juorio A, Macova M
-Regul Pept128p227-38(2005 Jun 30)
-)
-Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
-Cal LA, Maso LD, Caielli P, Pagnin E, Fusaro M, Davis PA, Pessina AC
-Blood Press20p376-82(2011 Dec)
-)
-Angiotensin receptors as determinants of life span.
-Cassis P, Conti S, Remuzzi G, Benigni A
-Pflugers Arch459p325-32(2010 Jan)
-)
-Role of renin-angiotensin system in inflammation, immunity and aging.
-Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF
-Curr Pharm Des18p963-70(2012)
-)
-Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
-Mason RP
-Vasc Health Risk Manag7p405-16(2011)
-== Olmesartan and other ARBs have been used ==
- to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:
-  * protect the heart from damage from inflammation in myocarditis20)
-  * ameliorate acute experimental autoimmune myocarditis, in rats, suppressing cytotoxic myocardial injury 21)
-  * prevent acute left ventricular dysfunction22)
-  * lower C-reactive protein, one of the acute phase proteins that increase during systemic inflammation23)
-  * act as an antiarrhythmic24)
-  * block the production of Angiotensin II, thus improving mortality rates in heart failure patients25)
-)
-Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3.
-Seko Y
-Clin Sci (Lond)110p379-86(2006 Mar)
-)
-Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure.
-Yuan Z, Nimata M, Okabe TA, Shioji K, Hasegawa K, Kita T, Kishimoto C
-Am J Physiol Heart Circ Physiol289pH1147-52(2005 Sep)
-)
-Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol.
-Ohta T, Hasebe N, Tsuji S, Izawa K, Jin YT, Kido S, Natori S, Sato M, Kikuchi K
-Am J Physiol Heart Circ Physiol287pH2914-21(2004 Dec)
-)
-C-reactive protein (CRP)-lowering agents.
-Prasad K
-Cardiovasc Drug Rev24p33-50(2006 Spring)
-)
-Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials.
-Boos CJ, Lip GY
-J Hum Hypertens19p855-9(2005 Nov)
-)
-Angiotensin II in the failing heart. Short communication.
-Schulz R, Heusch G
-Kidney Blood Press Res28p349-52(2005)
-)
-Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
-Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL
-N Engl J Med351p2058-68(2004 Nov 11)
-)
-Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.
-Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN
-Ann Intern Med148p16-29(2008 Jan 1)
-In August 2002, Trevor Marshall and Frances  Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARB caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.
-== Olmesartan has also been shown to ==
-  * prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes 29)
-  * reduce the volume of atherosclerotic plaques30) 31)
-  * mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).32)
-  * significantly remodel and destiffen the arterial wall material during long-term treatment 33).
-Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes.
-Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE
-J Hypertens32p2267-76; discussion 2276(2014 Nov)
-)
-Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
-Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M
-Ther Adv Cardiovasc Dis1p97-106(2007 Dec)
-)
-Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.
-Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T
-J Am Coll Cardiol55p976-82(2010 Mar 9)
-)
-A systematic review of angiotensin receptor blockers in preventing stroke.
-Lu GC, Cheng JW, Zhu KM, Ma XJ, Shen FM, Su DF
-Stroke40p3876-8(2009 Dec)
-)
-Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome.
-Laurent S, Boutouyrie P
-Hypertension64p709-16(2014 Oct)
-== A number of studies have found ==
- that olmesartan and other ARBs possess various ways of protecting the kidneys from the effects of inflammation and cytokine damage.
-  * in circadian rhythms between HR and MAP in CKD. Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization 34)
-  * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition 35)
-  * results suggest olmesartan can help decrease plasma AGE levels in patients on HD 36)
-  * renal protective effects of olmesartan may be better than those of other ARBs 37)
-  * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects 38)
-)
-Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure.
-Sato R, Mizuno M, Miura T, Kato Y, Watanabe S, Fuwa D, Ogiyama Y, Tomonari T, Ota K, Ichikawa T, Shirasawa Y, Ito A, Yoshida A, Fukuda M, Kimura G
-J Hypertens31p1233-8(2013 Jun)
-)
-The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
-Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S
-Hypertens Res36p262-9(2013 Mar)
-)
-Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
-Honda H, Hosaka N, Aoshima Y, Hirai Y, Michihata T, Akizawa T
-Clin Exp Hypertens34p17-23(2012)
-)
-A possible role of antihypertensive polar renomedullary lipid (APRL) and prostaglandin E2 in the kidney in the antihypertensive action of pindolol.
-Matsudaira T, Kogo H, Satoh T
-Res Commun Chem Pathol Pharmacol49p65-9(1985 Jul)
-)
-Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
-Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, Shibata S, Tanaka M, Watanabe Y, Akasaka H, Ohnishi H, Yoshida H, Takizawa H, Saitoh S, Ura N, Shimamoto K, Miura T
-Am J Hypertens28p15-21(2015 Jan)
-== Recent studies showed ==
-  * treatment with olmesartan inhibited bone loss 39)
-  * olmesartan protects endothelial cells against oxidative stress-mediated cellular injury 40)
-  * carotid IMT and BP decreased similarly with olmesartan and atenolol, but only olmesartan reduced the volume of larger atherosclerotic plaques 41)
-  * improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan 42)
-  * improvement of glycemic control & insulin resistance was only observed in olmesartan group 43)
-  * OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes 44)
-  * prevention of microalbuminuria in patients with type 2 diabetes and hypertension 45).
-data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.
-[ https://hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint ]
-)
-Effect of angiotensin II receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome.
-Aoki M, Kawahata H, Sotobayashi D, Yu H, Moriguchi A, Nakagami H, Ogihara T, Morishita R
-Geriatr Gerontol Int15p1064-72(2015 Aug)
-)
-Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury.
-Kadowaki D, Anraku M, Sakaya M, Hirata S, Maruyama T, Otagiri M
-Clin Exp Nephrol19p1007-14(2015 Dec)
-)
-Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
-Tada Y, Yagi K, Uno M, Matsushita N, Kanematsu Y, Kuwayama K, Shimada K, Nishi K, Hirasawa M, Satomi J, Kitazato KT, Kageji T, Matsuura E, Nagahiro S
-J Stroke Cerebrovasc Dis24p1487-92(2015 Jul)
-)
-Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
-Arao T, Okada Y, Mori H, Nishida K, Tanaka Y
-Endocr J60p563-70(2013)
-)
-Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.
-Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H
-J Hypertens30p811-8; discussion 818(2012 Apr)
-)
-Porphyria cutanea tarda induced by olmesartan.
-Mas-Vidal A, Coto-Segura P, García-Varona A, Santos-Juanes J
-J Eur Acad Dermatol Venereol24p977-8(2010 Aug)
-)
-Angiotensin-II behaves as an endogenous pro-inflammatory molecule.
-Das UN
-J Assoc Physicians India53p472-6(2005 May)

home/diseases/aging.txt · Last modified: 09.14.2022 by 127.0.0.1